1-14 of 14
Patrick Neven
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.

Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A. Kaufman, Nadia Harbeck, Kelly K. Hunt, Stacey Carter, Francois-Clement Bidard, Peter A. Fasching, Philippe Aftimos, Duncan Wheatley, Erika Hamilton, Rebecca Aft, Swati Kulkarni, Peter Schmid, Manali Bhave, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Bastien Nguyen, Umut Ozbek, Eunice Yuen, Vanessa Rodrik-Outmezguine, Eva Ciruelos
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-2113
Published: 08 October 2024
View article titled, A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.
Open the PDF for A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study. in another window
Includes: Supplementary data
Journal Articles

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4299–4309.
https://doi.org/10.1158/1078-0432.CCR-24-1073
Published: 01 October 2024
View article titled, Elacestrant in ER<sup>+</sup>, HER2<sup>−</sup> Metastatic Breast Cancer with <em>ESR1</em>-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Open the PDF for Elacestrant in ER<sup>+</sup>, HER2<sup>−</sup> Metastatic Breast Cancer with <em>ESR1</em>-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups in another window
Includes: Supplementary data
Journal Articles

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features

Hanne Lefrère, Kat Moore, Giuseppe Floris, Joyce Sanders, Iris M. Seignette, Tycho Bismeijer, Dennis Peters, Annegien Broeks, Erik Hooijberg, Kristel Van Calsteren, Patrick Neven, Ellen Warner, Fedro Alessandro Peccatori, Sibylle Loibl, Charlotte Maggen, Sileny N. Han, Katarzyna J. Jerzak, Daniela Annibali, Diether Lambrechts, Karin E. de Visser, Lodewyk Wessels, Liesbeth Lenaerts, Frédéric Amant
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3729–3743.
https://doi.org/10.1158/1078-0432.CCR-22-3645
Published: 15 September 2023
View article titled, Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Open the PDF for Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features in another window
Includes: Supplementary data
Journal Articles

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4587.
https://doi.org/10.1158/1078-0432.CCR-22-2874
Published: 14 October 2022
View article titled, Correction: Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Correction: Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Journal Articles

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1500–1506.
https://doi.org/10.1158/1078-0432.CCR-21-3276
Published: 14 April 2022
View article titled, Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Includes: Supplementary data
Journal Articles

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

Patrick Neven, Stephen R.D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C. Hurt, Antonio Llombart-Cussac, George W. Sledge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5801–5809.
https://doi.org/10.1158/1078-0432.CCR-20-4685
Published: 01 November 2021
View article titled, MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Open the PDF for MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

Elena Guerini-Rocco, Kathryn P. Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Paola Rafaniello Raviele, Elisabetta Munzone, Roswitha Kammler, Patrick Neven, Erika Hitre, Guy Jerusalem, Edda Simoncini, Andrea Gombos, Ines Deleu, Per Karlsson, Stefan Aebi, Jacquie Chirgwin, Vincenzo Di Lauro, Alastair Thompson, Marie-Pascale Graas, Matthew Barber, Christel Fontaine, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Bettina Müller, Seamus O’Reilly, Angelo Di Leo, Aron Goldhirsch, Giuseppe Viale, Massimo Barberis, Meredith M. Regan, Marco Colleoni
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 504–512.
https://doi.org/10.1158/1078-0432.CCR-20-0126
Published: 19 January 2021
View article titled, Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Open the PDF for Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial in another window
Includes: Supplementary data
Journal Articles

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme, Diether Lambrechts, An Poppe, Hans Wildiers, Anne-Sophie Dieudonné, Olivier Brouckaert, Jan Decloedt, Patrick Berteloot, Didier Verhoeven, Markus Joerger, Peter Vuylsteke, Wim Wynendaele, Minne Casteels, Sabine Van Huffel, Willem Lybaert, Johan Van Ginderachter, Robert Paridaens, Ignace Vergote, Vincent Olaf Dezentjé, Ben Van Calster, Henk-Jan Guchelaar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2312–2318.
https://doi.org/10.1158/1078-0432.CCR-17-3028
Published: 14 May 2018
View article titled, Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Open the PDF for Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial in another window
Includes: Supplementary data
Journal Articles

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses

Adriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, Chiara Landolfo, Els Van Nieuwenhuysen, Karin Leunen, Patrick Neven, Frédéric Amant, Sven Mahner, Elena Ioana Braicu, Robert Zeilinger, An Coosemans, Dirk Timmerman, Diether Lambrechts, Ignace Vergote
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (9): 2223–2231.
https://doi.org/10.1158/1078-0432.CCR-16-1078
Published: 30 April 2017
View article titled, Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses
Open the PDF for Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses in another window
Includes: Supplementary data
Journal Articles

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

Weimin Li, Joyce O'Shaughnessy, Daniel Hayes, Mario Campone, Igor Bondarenko, Irina Zbarskaya, Etienne Brain, Marina Stenina, Olga Ivanova, Marie-Pascale Graas, Patrick Neven, Deborah Ricci, Thomas Griffin, Thian Kheoh, Margaret Yu, Michael Gormley, Jason Martin, Michael Schaffer, Kathy Zelinsky, Peter De Porre, Stephen R.D. Johnston
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (24): 6002–6009.
https://doi.org/10.1158/1078-0432.CCR-15-2452
Published: 15 December 2016
View article titled, Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, Sylvain Brohée, E. Marielle Hijmans, Bastiaan Evers, Debora Fumagalli, Christine Desmedt, Sibylle Loibl, Carsten Denkert, Patrick Neven, Wei Guo, Fan Zhang, Theo A. Knijnenburg, Tjalling Bosse, Michiel S. van der Heijden, Sanne Hindriksen, Wouter Nijkamp, Lodewyk F.A. Wessels, Heikki Joensuu, Gordon B. Mills, Roderick L. Beijersbergen, Christos Sotiriou, René Bernards
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5238–5248.
https://doi.org/10.1158/1078-0432.CCR-15-2996
Published: 31 October 2016
View article titled, Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Open the PDF for Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

C. Kent Osborne, Patrick Neven, Luc Y. Dirix, John R. Mackey, Jean Robert, Craig Underhill, Rachel Schiff, Carolina Gutierrez, Ilenia Migliaccio, Valsamo K. Anagnostou, David L. Rimm, Patrick Magill, Mark Sellers
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1147–1159.
https://doi.org/10.1158/1078-0432.CCR-10-1869
Published: 01 March 2011
View article titled, Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
Open the PDF for Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study in another window
Journal Articles

A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer

Antonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, Rodica M. Anghel, Alexandra E. Eniu, Mark W. Verrill, Patrick Neven, Jacques De Grève, Allen S. Melemed, Romnee Clark, Lorinda Simms, Christopher J. Kaiser, Doreen Ma
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3652–3659.
https://doi.org/10.1158/1078-0432.CCR-06-2377
Published: 15 June 2007
View article titled, A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer
Open the PDF for A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer in another window
Journal Articles

Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology

Leilani Morales, Robert Paridaens, Dirk Timmerman, Patrick Neven
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5603.
https://doi.org/10.1158/1078-0432.CCR-06-0897
Published: 25 September 2006
View article titled, Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology
Open the PDF for Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology in another window